The study was funded by National Key Research and Development Program of China(2016YFC1305304);Beijing Children's Hospital Young Investigator Program(No.BCHYIPA-2016-06);Beijing Municipal Administration of Hospital Clinical Medicine Development of Special Funding Support(No.ZYLX201821).
Importance: Octreotide is an off-label medicine for congenital hyperinsulinism (CHI), but is currently widely used for treatment of patients with CHI. Thus far, variable efficacy and adverse effects have been reported...